Minerva Neurosciences, Inc.

NasdaqCM:NERV Stock Report

Market Cap: US$16.5m

Minerva Neurosciences Management

Management criteria checks 2/4

Minerva Neurosciences' CEO is Remy Luthringer, appointed in Nov 2014, has a tenure of 9.5 years. total yearly compensation is $1.84M, comprised of 34% salary and 66% bonuses, including company stock and options. directly owns 2.64% of the company’s shares, worth $436.15K. The average tenure of the management team and the board of directors is 8.1 years and 8.8 years respectively.

Key information

Remy Luthringer

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage34.0%
CEO tenure9.5yrs
CEO ownership2.6%
Management average tenure8.1yrs
Board average tenure8.8yrs

Recent management updates

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Minerva Neurosciences: Biotech On The Move

Aug 29

Minerva stock rises on filing for FDA approval of schizophrenia therapy

Aug 22

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Jun 22
We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03
Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27
What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23
We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18
A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Minerva Neurosciences EPS beats by $0.03

Nov 02

CEO Compensation Analysis

How has Remy Luthringer's remuneration changed compared to Minerva Neurosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$624k

-US$30m

Sep 30 2023n/an/a

-US$28m

Jun 30 2023n/an/a

-US$27m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$600k

-US$32m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$49m

Mar 31 2022n/an/a

-US$51m

Dec 31 2021US$1mUS$585k

-US$50m

Sep 30 2021n/an/a

-US$36m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

US$5m

Dec 31 2020US$2mUS$565k

US$2m

Sep 30 2020n/an/a

-US$21m

Jun 30 2020n/an/a

-US$27m

Mar 31 2020n/an/a

-US$69m

Dec 31 2019US$1mUS$543k

-US$72m

Sep 30 2019n/an/a

-US$55m

Jun 30 2019n/an/a

-US$54m

Mar 31 2019n/an/a

-US$54m

Dec 31 2018US$4mUS$525k

-US$50m

Sep 30 2018n/an/a

-US$37m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$33m

Dec 31 2017US$2mUS$445k

-US$32m

Compensation vs Market: Remy's total compensation ($USD1.84M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Remy's compensation has increased whilst the company is unprofitable.

CEO

Remy Luthringer (62 yo)

9.5yrs

Tenure

US$1,835,160

Compensation

Dr. Remy Luthringer, Ph D., serves as a Clinical Advisor to the Medicxi investment team and a Member of the Co-Founding team at Medicxi Ventures (UK) LLP. He has played an active role in several Index Vent...

Leadership Team

NamePositionTenureCompensationOwnership
Remy Luthringer
Executive Chairman & CEO9.5yrsUS$1.84m2.64%
$ 436.2k
Geoffrey Race
President2.6yrsUS$1.40m0.73%
$ 121.1k
Frederick Ahlholm
Senior VP2.6yrsUS$965.12k0.25%
$ 41.3k
Joseph Reilly
Senior VP & COO9.8yrsUS$1.49mno data
William Boni
Vice President of Investor Relations & Corporate Communications8.8yrsno datano data
Michael Davidson
Chief Medical Officer7.4yrsUS$657.47kno data

8.1yrs

Average Tenure

62yo

Average Age

Experienced Management: NERV's management team is seasoned and experienced (8.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Remy Luthringer
Executive Chairman & CEO9.5yrsUS$1.84m2.64%
$ 436.2k
Jeryl Hilleman
Independent Director5.8yrsUS$128.25k0.0018%
$ 295.4
G. van Heek
Independent Director9.8yrsUS$120.75k0.036%
$ 6.0k
Hans Hasler
Independent Director6.4yrsUS$127.00k0.018%
$ 2.9k
David Kupfer
Lead Independent Director8.5yrsUS$125.25k0.34%
$ 56.5k
Fouzia Laghrissi-Thode
Independent Director9yrsUS$122.25k0%
$ 0

8.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: NERV's board of directors are considered experienced (8.8 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.